Tango Therapeutics, Inc.
TNG462
PDAC
Countdown
358days
Phase 2 readout · ~ Jun 30, 2027 estimated
What's at stake
Phase 2 trial results for TNG462 in PDAC are due ~ Jun 30, 2027. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· ClinicalTrials.gov
verified 15h ago
“CT.gov NCT06922591: Phase 2 trial, sponsor Tango Therapeutics, Inc., drug TNG462. Primary completion date 2027-06 (estimated).”